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Background: Desmoid tumours/aggressive fibromatosis (DT/AF) are infrequent soft-tissue neoplasms. They usually
behave as indolent diseases. However, they may grow locally infiltrating or compressing adjacent structures. The
role of local treatment is limited and only a few drugs have shown activity.
Cases presentation: We report the outcome of two patients affected by progressive DT/AF treated with the
angiogenesis inhibitor pazopanib in two different institutions. Both patients achieved dramatic improvement in
their symptoms and radiological signs of response. The clinical benefit lasted for more than 1 year and it is still
ongoing.
Conclusions: Pazopanib is an active treatment in DT/AF. It is the first time this has been reported.
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Desmoid tumours/aggressive fibromatosis (DT/AF) are
rare soft-tissue neoplasms that usually arise from the
abdomen although extremities are also a common site
of presentation [1,2]. They may be associated with genetic
conditions such as Gardner’s syndrome [3]. Patients’
survival is usually good as DT/AF lack the capacity to
metastasize although anatomical disease site is important.
Interestingly, the treatment paradigm has changed in the
last decade. Aggressive upfront approaches are now under
debate since nearly 50% of patients have relatively indolent
disease [4]. Thus, surveillance at initial presentation is
the current standard of care in most centres. However,
it may become a symptomatic disease as it can grow
locally infiltrating or compressing adjacent structures [5].
Surgery is one treatment choice when technically feas-
ible however rates of recurrence and post-treatment mor-
bidity are high [6]. Radiotherapy is also an option but
there are real concerns surrounding late effects including
development of second malignancies which is important
to consider given the young age of most patients. When
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cepted strategy in first-line setting is hormone treat-
ment, based on the relatively frequent overexpression of
oestrogen receptors, used in combination with nonste-
roidal anti-inflammatory drugs (NSAIDs) [7,8]. If this
treatment proves ineffective, cytotoxic chemotherapy is
a valid alternative. Pegylated liposomal doxorubicin has
shown signs of activity although it is not without toxicity
[9]. Several targeted agents have been recently assessed
with promising results. The, tyrosine-kinase inhibitor
imatinib has been proven to have activity in phase II
studies [10,11]. Also, recent encouraging data with the
antiangiogenic drug sorafenib have been published
where the rate of clinical benefit was very high (70%). In
addition, partial response (PR) and stable disease (SD)
rates were 25% and 70% respectively. Furthermore, 92%
of patients showed features of increased tumour fibrosis
and loss of cellularity as demonstrated by an early change
in MRI T2 signal [12]. These data support further
investigation into the role of antiangiogenic agents in
DT/AF.
Pazopanib is one of the latest antiangiogenic drugs de-
veloped. It has recently been approved by the U.S. Food
and Drug Administration (FDA) and by the European
Medicines Agency (EMA) for the treatment of advanced
renal cancer and soft-tissue sarcomas (STS). We presententral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Figure 1 Axial T2 weighted MRI images of the thorax at
baseline (a) and following 10 months of pazopanib (b). A large
plaque of fibromatosis encases the lateral right hemithorax
extending into the axilla. Although the disease remained
dimensionally stable the lateral component (arrows) demonstrated
T2 signal drop from intermediate to low indicating a reduction
in cellularity.
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DT/AF. These encouraging results might be the initial
step in the development of a new effective therapy this
challenging disease.
Cases presentation
This is the report of the clinical outcome of two patients
affected by unresectable DT/AF treated with pazopanib
in two different UK institutions: The Royal Marsden
Hospital, London and Belfast City Hospital, Belfast. Data
were retrospectively collected and imaging was reviewed
by a Sarcoma Unit radiologist from The Royal Marsden
Hospital.
Patient 1
Patient 1 is a female who presented at the age of 42 years
with a painful mass in the right axilla. A biopsy showed
features consistent with DT/AF. The patient did not
have personal or family history of Gardner’s syndrome
or colonic polyps. Surgical resection was performed in
two occasions but residual disease remained. As the pain
in the axilla increased, treatment with tamoxifen 40 mg
once daily (od) was initiated one year after the second
surgery. However, there was an increase in the size of the
mass and worsening of symptoms in the form of restricted
movement and neuropathic pain, so pegylated liposomal
doxorubicin was advised. Unfortunately, chemotherapy
had to be stopped after one cycle due to an allergic
reaction. Subsequent treatment with methotrexate and
vinblastine was given. Symptoms were stabilized although
the patient experienced disabling toxicities such as severe
constipation and neuropathy. After five months, an MRI
showed progressive disease (PD), the tumour measuring
15 × 5.9 cm.
At this point, treatment with pazopanib 800 mg od
was started. Shortly afterwards, the patient developed
hypertension, dysgeusia and mild palmar erythema so
the dose was reduced to 600 mg od. After two months,
the patient reported a significant improvement in her
pain. Analgesic requirements were dramatically reduced
and an MRI showed no changes in size but a significant
reduction in tumour T2 signal intensity, suggesting
reduction in cellularity. Six months after starting pazo-
panib, a further dose reduction due to diarrhoea was
needed (400 mg od). At that time, a second assessment
MRI showed maintained SD and the drop in T2 signal in-
tensity compared to baseline remained suggesting contin-
ued response (Figure 1). In the following months, further
toxicities appeared: skin rash, peripheral neuropathy and
worsening hypertension, dysgeusia and diarrhoea. These
side effects led to a further dose reduction to 200 mg od
and optimization of supportive treatment.
The patient is currently tolerating pazopanib without
significant side effects. Furthermore, her tumour hasremained stable in size but with T2 changes in MRI
suggestive of response for nearly eighteen months. The
clinical benefit has been very clear and in particular
pain is well controlled, which was the main factor
impairing the patient’s quality of life.
Patient 2
Patient 2 is a female who presented at the age of 16 years
with a painful left axillary mass. The histological analysis
was consistent with DT/AF. The patient did not have a
history of Gardner´s syndrome or colonic polyps. Incom-
plete resection was performed and for the following ten
years the patient remained asymptomatic. After that time,
she developed pain and impairment in the abduction of
her left arm. An MRI confirmed tumour recurrence, with
involvement of the triceps and inferior deltoid muscles.
Surgery was not advised and the patient was started on
systemic treatment with high dose NSAIDs; three months
on MRI scan showed no significant changes and limitation
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treatment, the patient became pregnant and treatment
was discontinued. Unfortunately, shortly after the
symptoms dramatically worsened. Pegylated liposomal
doxorubicin was initiated when the patient was in the
third trimester of her pregnancy but with no radio-
logical nor symptomatic benefit. As there were con-
tinued significant limitations in arm movement, the
patient was very keen to pursue further treatment.
Therefore, tumour resection followed by radiotherapy
was performed. After these procedures, the patienta
c
Figure 2 Axial T2 weighted and coronal STIR MRI images of the proxi
pazopanib (c and d). A large focus of fibromatosis expands the triceps m
10.2 cm in maximum craniocaudal dimension to 8.0 cm. Predominantly int
reduction in signal (c and d, arrows) indicating diminished cellularity.regained an almost complete range of movement in
her arm.
One year after her last operation, an MRI showed two
new sites of disease. These findings were associated with
worsening of the pain in spite of NSAIDs. Tamoxifen, to-
gether with continuation of high dose NSAIDs, was then
prescribed. Six months on, further tumour growth and
worsening symptoms suggested that the treatment was
ineffective.
A new line of treatment with pazopanib 800 mg od
was started. After two weeks of treatment, significantb
d
mal left arm at baseline (a and b) and following 11 months of
uscle and following 11 months of treatment reduced in size from
ermediate/high signal tissue (a and b, arrows) showed a marked
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first assessment MRI after three months demonstrated
reduction in tumour size (from 10.2 × 4.2 cm at baseline
to 9 × 3.1 cm). Mild diarrhoea and fatigue were the only
side effects. Subsequent MRIs showed further tumour
shrinkage and reduction in T2 signal (Figure 2). In
addition, mobility of patient’s left arm progressively im-
proved. The patient remains on full dose of pazopanib
without significant toxicities and with ongoing clinical and
radiological benefit more than one year since starting
pazopanib.
Conclusions
This report demonstrates for the first time that pazopanib
is an active treatment in DT/AF.
The lack of effective therapeutic options and its high
morbidity make DT/AF a challenging disease. The
promising results observed with sorafenib suggested
that angiogenesis might play an important role in this
condition [12]. Although DT/AF is not strictly consid-
ered a malignancy, the mechanisms that lead to uncon-
trolled monoclonal cellular proliferation and survival
are similar to those in cancer [13]. Angiogenesis is one
of the most important processes in carcinogenesis and
its relevance in soft-tissue tumours has also been dem-
onstrated [14]. Several studies confirm the key role of
some of its effectors such as the vascular endothelial
growth factor (VEGF) and the different isoforms of its
receptor (VEGFR) [15-19]. Another crucial protein in
the formation of new tumour vessels is the platelet-
derived growth factor PDGF [20]. Interestingly, both
sorafenib and pazopanib inhibit both VEGFR and the
PDGF receptor (PDGFR) [21]. Conversely imatinib -a
tyrosine-kinase inhibitor which also demonstrates prom-
ising activity in DT/AF [10,11]- has effects on PDGFR but
not on VEGFR [22]. These data suggest that the efficacy
of these drugs in DT/AF might be due to their antian-
giogenic activity mediated by the inhibition of different
key effectors.
Pazopanib is the first antiangiogenic drug that has
shown successful results in a phase III trial in STS [23].
We demonstrate in this report is that it is also active in
DT/AF. Furthermore although it has side effects, as
shown in Patient 1, it is generally better tolerated than
conventional chemotherapy. This is crucial in a disease
such as DT/AF, where curative options are scarce and
the principal aim of the treatment is to improve quality
of life. In addition, clinical benefit lasted for over one
year in both cases and it is still ongoing. Fortunately, the
relative lack of cumulative toxicity of pazopanib compared
to standard chemotherapy allows an indeterminate
duration of treatment.
In conclusion, pazopanib is a promising therapeutic
option in DT/AF. However, owing to the retrospectivenature of this report and the small number of patients
this observation clearly needs to be confirmed in prospect-
ive studies. Thus, the French Sarcoma Group is currently
conducting a phase II trial that assesses the efficacy and
tolerance of pazopanib in DT/AF (ClinicalTrials.gov
identifier NCT01876082). This encouraging novel strat-
egy deserves further investigation.
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